-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, L5PPdiqjsSWH9wCEZg/m0fWsJu1wgXOkOL1YulhiEvANm0lAX9z2kfMPdCE+7SY6 PB0l/EkElWUmyO1rBWcSCA== 0001019056-07-000026.txt : 20070112 0001019056-07-000026.hdr.sgml : 20070112 20070112143003 ACCESSION NUMBER: 0001019056-07-000026 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070112 DATE AS OF CHANGE: 20070112 GROUP MEMBERS: BIO PARTNERS LP GROUP MEMBERS: JEFFREY K. VOGEL GROUP MEMBERS: JON M. VOGEL GROUP MEMBERS: SHERMAN C. VOGEL SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79091 FILM NUMBER: 07528372 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIO PARTNERS LP CENTRAL INDEX KEY: 0001240418 IRS NUMBER: 753109883 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 1 MEADOW DRIVE CITY: LAWRENCE STATE: NY ZIP: 11559 BUSINESS PHONE: 516 295 1762 SC 13G/A 1 biospecifics_13ga3.txt SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3)* Biospecifics Technologies Corp. ------------------------------------------------------------ (Name of Issuer) Common Stock, $.001 par value ------------------------------------------------------------ (Title of Class of Securities) 090931106 ------------------------ (CUSIP Number) Jeffrey K. Vogel Bio Partners LP 1 Meadow Drive Lawrence, New York 11559 Telephone: (516) 295-1762 ------------------------------------------------------------ (Name, Address and Telephone Number of Persons Authorized to Receive Notices and Communications) December 31, 2006 ------------------------------------------------------------ (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13G - ------------------------- ---------------------- CUSIP No. 090931106 Page 2 of 11 Pages - ------------------------- ---------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Bio Partners LP S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [__________________] - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OR ORGANIZATION Delaware - -------------------------------------------------------------------------------- NUMBER OF SHARES 5 SOLE VOTING POWER 0 BENEFICIALLY OWNED --------------------------------------------------- BY EACH REPORTING 6 SHARED VOTING POWER 295,312(1) PERSON WITH --------------------------------------------------- 7 SOLE DISPOSITIVE POWER 0 --------------------------------------------------- 8 SHARED DISPOSITIVE POWER 295,312(1) - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 295,312(1) - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) N/A - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.3% (2) - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (See Instructions) PN - -------------------------------------------------------------------------------- (1) Bio Partners LP, a Delaware limited partnership, has a sole general partner, Bio Management, Inc., a New York corporation ("Bio Management"), and Bio Management's sole shareholder and President is Jeffrey K. Vogel. Mr. Vogel thus has the power to vote or dispose of the 295,312 shares of common stock, $.001 par value ("Common Stock") of Biospecifics Technologies Corp. ("Biospecifics") owned by Bio Partners LP. (2) Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s Common Stock outstanding as of November 9, 2005, as reported in its proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 2, 2005. 2 SCHEDULE 13G - ------------------------- ---------------------- CUSIP No. 090931106 Page 3 of 11 Pages - ------------------------- ---------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Jeffrey K. Vogel S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [___________________] - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OR ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF SHARES 5 SOLE VOTING POWER 149,640 BENEFICIALLY OWNED --------------------------------------------------- BY EACH REPORTING 6 SHARED VOTING POWER 295,312(1) PERSON WITH --------------------------------------------------- 7 SOLE DISPOSITIVE POWER 149,640 --------------------------------------------------- 8 SHARED DISPOSITIVE POWER 295,312(2) - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 444,952(3) - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) N/A - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.0% (4) - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- (1) Mr. Vogel is the sole shareholder and President of Bio Management, which is the sole general partner of Bio Partners LP. Mr. Vogel thus has the power to vote these 295,312 shares of Common Stock owned by Bio Partners LP. (2) Mr. Vogel is the sole shareholder and President of Bio Management, which is the sole general partner of Bio Partners LP. Mr. Vogel thus has the power to dispose these 295,312 shares of Common Stock owned by Bio Partners LP. (3) Includes (i) 149,640 shares of Common Stock held directly by Jeffrey K. Vogel and (ii) 295,312 shares of Common Stock held by Bio Partners LP. (4) Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s Common Stock outstanding as of November 9, 2005, as reported in its proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 2, 2005. 3 SCHEDULE 13G - ------------------------- ---------------------- CUSIP No. 090931106 Page 4 of 11 Pages - ------------------------- ---------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Jon M. Vogel S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [___________________] - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OR ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF SHARES 5 SOLE VOTING POWER 149,566 BENEFICIALLY OWNED --------------------------------------------------- BY EACH REPORTING 6 SHARED VOTING POWER 0 PERSON WITH --------------------------------------------------- 7 SOLE DISPOSITIVE POWER 0 --------------------------------------------------- 8 SHARED DISPOSITIVE POWER 149,566(1) - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 149,566 - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) N/A - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.7%(1) - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- (1) Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s Common Stock outstanding as of November 9, 2005, as reported in its proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 2, 2005. 4 SCHEDULE 13G - ------------------------- ---------------------- CUSIP No. 090931106 Page 5 of 11 Pages - ------------------------- ---------------------- - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON: Sherman C. Vogel S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: [___________________] - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OR ORGANIZATION United States - -------------------------------------------------------------------------------- NUMBER OF SHARES 5 SOLE VOTING POWER 148,107 BENEFICIALLY OWNED --------------------------------------------------- BY EACH REPORTING 6 SHARED VOTING POWER 0 PERSON WITH --------------------------------------------------- 7 SOLE DISPOSITIVE POWER 148,107 --------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 148,107 - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) N/A - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.7% (1) - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON (See Instructions) IN - -------------------------------------------------------------------------------- (1) Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s Common Stock outstanding as of November 9, 2005, as reported in its proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 2, 2005. 5 Item 1. (a) Name of Issuer: -------------- Biospecifics Technologies Corp. ("Biospecifics") (b) Address of Issuer's Principal Executive Offices: ----------------------------------------------- 35 Wilbur Street, Lynbrook, New York 11563 Item 2. (a) Name of Persons Filing: ---------------------- Bio Partners LP Jeffrey K. Vogel Jon M. Vogel Sherman C. Vogel (b) Address of Principal Business Office or, if none, Residence: ----------------------------------------------------------- (i) The address of each Bio Partners LP and Jeffrey K. Vogel is: 1 Meadow Drive Lawrence, NY 11559 (ii) The address of Jon M. Vogel is: 17020 Brookwood Drive Boca Raton, FL 33496 (iii) The address of Sherman C. Vogel is: 7110 Melrose Castle Lane Boca Raton, FL 33496 (c) Citizenship: ----------- Bio Partners LP is a Delaware limited partnership. Jeffrey K. Vogel, Jon M. Vogel and Sherman C. Vogel are each a citizen of the United States. (d) Title of Class of Securities: ---------------------------- Common Stock, par value $.001 per share (the "Common Stock") (e) CUSIP Number: ------------ 090931106 Item 3. This statement is not being filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c). 6 Item 4. Ownership (a) Amount beneficially owned: ------------------------- Bio Partners LP beneficially owns 295,312 shares of Biospecifics' Common Stock. Jeffrey K. Vogel beneficially owns 444,952 shares of Biospecifics' Common Stock, which includes (i) 149,640 shares of Common Stock held directly by Jeffrey K. Vogel and (ii) 295,312 shares of Common Stock held by Bio Partners LP. Jon M. Vogel beneficially owns 149,566 shares of Biospecifics' Common Stock. Sherman C. Vogel beneficially owns 148,107 shares of Biospecifics' Common Stock. Together, the reporting persons beneficially own 742,625 shares of Biospecifics' Common Stock. (b) Percent of class: ---------------- Calculated based on 5,535,216 shares of Biospecifics Technologies Corp.'s Common Stock outstanding as of November 9, 2005, as reported in its proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 2, 2005. Bio Partners LP has beneficial ownership of 5.3% of all of the outstanding shares of Biospecifics' Common Stock. Jeffrey K. Vogel has beneficial ownership of 8.0% of all of the outstanding shares of Biospecifics' Common Stock. Jon M. Vogel has beneficial ownership of 2.7% of all of the outstanding shares of Biospecifics' Common Stock. Sherman C. Vogel has beneficial ownership of 2.7% of all of the outstanding shares of Biospecifics' Common Stock. Together, the reporting persons have beneficial ownership of 13.4% percent of all of the outstanding shares of Biospecifics' Common Stock. (c) Number of shares as to which the person has: ------------------------------------------- (i) Sole power to vote or to direct the vote: ---------------------------------------- Bio Partners LP has the sole power to vote or direct the vote of 0 shares of Biospecifics' Common Stock. 7 Jeffrey K. Vogel has the sole power to vote or direct the vote of 149,640 shares of Biospecifics' Common Stock. Jon M. Vogel has the sole power to vote or direct the vote of 149,566 shares of Biospecifics' Common Stock. Sherman C. Vogel has the sole power to vote or direct the vote of 148,107 shares of Biospecifics' Common Stock. (ii) Shared power to vote or to direct the vote: ------------------------------------------ Bio Partners LP has shared power to vote or direct the vote of 295,312 shares of Biospecifics' Common Stock. Jeffrey K. Vogel is the sole shareholder and President of Bio Management, Inc., a New York corporation ("Bio Management"), which is the sole general partner of Bio Partners LP. Mr. Vogel thus has the power to vote or dispose of the 295,312 shares of Biospecifics' Common Stock owned by Bio Partners LP. Jeffrey K. Vogel has shared power to vote or direct the vote of 295,312 shares of Biospecifics' Common Stock with Bio Partners LP. Jon M. Vogel has shared power to vote or direct the vote of 0 shares of Biospecifics' Common Stock. Sherman C. Vogel has shared power to vote or direct the vote of 0 shares of Biospecifics' Common Stock. (iii) Sole power to dispose or to direct the disposition of: ----------------------------------------------------- Bio Partners LP has the sole power to dispose or direct the disposition of 0 shares of Biospecifics' Common Stock. Jeffrey K. Vogel has the sole power to dispose or direct the disposition of 149,640 shares of Biospecifics' Common Stock. Jon M. Vogel has the sole power to dispose or direct the disposition of 149,566 shares of Biospecifics' Common Stock. Sherman C. Vogel has the sole power to dispose or direct the disposition of 148,107 shares of Biospecifics' Common Stock. (iv) Shared power to dispose or to direct the disposition of: ------------------------------------------------------- Bio Partners LP has the shared power to dispose or direct the disposition of 295,312 shares of Biospecifics' Common Stock. Jeffrey K. Vogel is the sole shareholder and President of Bio Management, the sole general partner of Bio Partners LP. Mr. Vogel thus has the power to vote or dispose of the 295,312 shares of Common Stock owned by Bio Partners LP. 8 Jeffrey K. Vogel has the shared power to dispose or direct the disposition of 295,312 shares of Biospecifics' Common Stock owned by Bio Partners LP. Jon M. Vogel has the shared power to dispose or direct the disposition of 0 shares of Biospecifics' Common Stock. Sherman C. Vogel has the shared power to dispose or direct the disposition of 0 shares of Biospecifics' Common Stock. Item 5. Ownership of Five Percent or Less of a Class Not Applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person Not applicable. Item 8. Identification and Classification of Members of the Group Not Applicable Item 9. Notice of Dissolution of Group Not Applicable Item 10. Certification (b) This Schedule 13G Amendment is being filed pursuant to Rule 13d-1(c): By signing below we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 9 SIGNATURE After reasonable inquiry and to the best of each undersigned's knowledge and belief, the undersigned hereby certify that the information set forth in this Statement is true, complete and correct. January 10, 2007 BIO PARTNERS LP By: Bio Management, Inc., its sole general partner By: /s/ JEFFREY K. VOGEL ------------------------------------- Name: Jeffrey K. Vogel Title: President /s/ JEFFREY K. VOGEL ------------------------------------- Jeffrey K. Vogel /s/ JON M. VOGEL ------------------------------------- Jon M. Vogel /s/ SHERMAN C. VOGEL ------------------------------------- Sherman C. Vogel 10 EXHIBIT A JOINT FILING AGREEMENT The undersigned agree that this Amendment No. 3 to Schedule 13G filed herewith relating to the shares of common stock of Biospecifics Technologies Corp. is filed jointly on behalf of each of the undersigned pursuant to Rule 13d-1(k) under the Exchange Act. January 10, 2007 BIO PARTNERS LP By: Bio Management, Inc., its sole general partner By: /s/ JEFFREY K. VOGEL ------------------------------------- Name: Jeffrey K. Vogel Title: President /s/ JEFFREY K. VOGEL ------------------------------------- Jeffrey K. Vogel /s/ JON M. VOGEL ------------------------------------- Jon M. Vogel /s/ SHERMAN C. VOGEL ------------------------------------- Sherman C. Vogel 11 -----END PRIVACY-ENHANCED MESSAGE-----